Investing

Glaxosmithkline Ups Stake in Spero Therapeutics Inc (SPRO)

13threephotography / iStock Editorial via Getty Images

Fintel reports that Glaxosmithkline Plc has filed a 13D/A form with the SEC disclosing ownership of 9,190,606 shares of Spero Therapeutics Inc (SPRO). This represents 19.99% of the company.

In their previous filing dated September 16, 2021 they reported 1,740,606 shares and 5.40% of the company, an increase in shares of 428.01% and an increase in total ownership of 14.59% (calculated as current – previous percent ownership).

Spero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug-resistant (MDR) bacterial infections and rare diseases.

What are other large shareholders doing?

Aquilo Capital Management, LLC holds 5,321,231 shares representing 12.52% ownership of the company. In it’s prior filing, the firm reported owning 5,281,504 shares, representing an increase of 0.75%. The firm decreased its portfolio allocation in SPRO by 80.07% over the last quarter.

Bvf Inc/il holds 3,089,615 shares representing 7.27% ownership of the company. In it’s prior filing, the firm reported owning 1,585,615 shares, representing an increase of 48.68%. The firm decreased its portfolio allocation in SPRO by 79.97% over the last quarter.

Atlas Venture Associates IX, LLC holds 1,376,968 shares representing 3.24% ownership of the company. No change in the last quarter.

Atlas Venture Life Science Advisors, LLC holds 1,031,160 shares representing 2.43% ownership of the company. No change in the last quarter.

Renaissance Technologies Llc holds 939,017 shares representing 2.21% ownership of the company. In it’s prior filing, the firm reported owning 109,100 shares, representing an increase of 88.38%. The firm decreased its portfolio allocation in SPRO by 26.01% over the last quarter.

What is the overall institutional sentiment?

There are 188 funds or institutions reporting positions in Spero Therapeutics Inc. This is a decrease of 34 owner(s) or 15.32%.

Average portfolio weight of all funds dedicated to Spero Therapeutics Inc is 0.0581%, a decrease of 5.9867%. Total shares owned by institutions decreased in the last three months by 0.80% to 20,401,134 shares.

Based on this information, institutional sentiment is bearish.

This article originally appeared on Fintel

Sponsored: Want to Retire Early? Here’s a Great First Step

Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?

Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.

Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.